[Early use of recombinant human erythropoietin promotes neurobehavioral development in preterm infants].
Zhongguo Dang Dai Er Ke Za Zhi
; 10(5): 586-8, 2008 Oct.
Article
em Zh
| MEDLINE
| ID: mdl-18947475
ABSTRACT
OBJECTIVE:
To evaluate the effect of the early use of recombinant human erythropoietin (rhu-EPO) on neurobehavioral development in preterm infants.METHODS:
Forty-four preterm infants (30 males and 14 females) were randomly divided into two groups Rhu-EPO treatment and untreated control (n=22 each). From postnatal day 7, the Rhu-EPO treatment group received intravenous rhu-EPO (250 IU/kg3 times weekly) for 4 weeks. A Neonatal Behavioral Neurological Assessment (NBNA) was performed at 40 weeks of corrected gestational age. A Gesell Development Schedule was used to evaluate neurological development 6 and 12 months after birth.RESULTS:
The NBNA score in the rhu-EPO treatment group (36.20+/-0.75) was significantly higher than that in the control group (34.40+/-1.05) at 40 weeks of corrected gestational age (P<0.05). The developmental quotient of fine motor in the rhu-EPO treatment group was significantly higher than that in the control group 6 months after birth (P<0.05). By 12 months after birth, the developmental quotient of gross motor, fine motor and language in the rhu-EPO treatment group was significantly higher than that in the control group (P<0.05).CONCLUSIONS:
Early use of Rhu-EPO can promote neurobehavioral development in preterm infants.
Buscar no Google
Base de dados:
MEDLINE
Assunto principal:
Encéfalo
/
Recém-Nascido Prematuro
/
Desenvolvimento Infantil
/
Eritropoetina
/
Comportamento do Lactente
/
Doenças do Prematuro
/
Anemia
Tipo de estudo:
Clinical_trials
Limite:
Female
/
Humans
/
Male
/
Newborn
Idioma:
Zh
Ano de publicação:
2008
Tipo de documento:
Article